DCA was proposed as a possible cancer therapy, although it was unknown its possible use as cutaneous melanoma therapy. A team of IPATIMUP researchers published a study in Expert Opinion on Therapeutic Targets, where they evaluated the expression profile of pyruvate dehydrogenase kinase isoforms, the DCA targets, in a series of melanoma samples and nevi, and also established the sensitivity of melanoma cell lines to DCA treatment.